United States expands statin eligibility to 87.5 million adults under new cholesterol guidelines

The 2026 American cholesterol guideline lowers the age at which adults may be prescribed statins from 40 to 30 years, expanding eligibility to an estimated 87.5 million people aged 30‑79. The change adds about 21.5 million new candidates, with more than 93 % of those aged 70‑79 and 85 % of those 60‑69 now qualifying, compared with only 11 % of the 30‑39 age group under previous rules. The recommendation was led by internal‑medicine researcher Timothy Anderson of the University of Pittsburgh and endorsed by the American Heart Association and other societies.

A concurrent global analysis published in JAMA quantified that elevated LDL‑C caused 3.6 million deaths in 2023, representing 6 % of all mortality and 90.7 million lost healthy life years. The burden was highest in India and China, which together accounted for one‑third of LDL‑C‑related deaths. The study highlighted LDL‑C as the second leading risk factor for cardiovascular disease worldwide.

Similar guideline updates have been adopted in Spain, reflecting a broader shift toward earlier and wider use of cholesterol‑lowering therapy.